Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update Compass Therapeutics announces 2nd quarter results and provides clinical results update

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...